Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara

References

• Webster RG, Bean WJ. Evolution and ecology of influenza viruses: interspecies transmission. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK 109–119 (1998).
   Google Scholar
• Potter CW. Chronicle of influenza pandemics. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK 3–18 (1998).
   Google Scholar
• Claas EC, Osterhaus AD, van Beek R et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet351(9101), 472–477 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature389(6651), 554 (1997).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Klimov A, Katz J et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science279(5349), 393–396 (1998).
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Ungchusak K, Sovann L et al. Family clustering of avian influenza A (H5N1). Emerg. Infect. Dis.11(11), 1799–1801 (2005).
   PubMed Web of Science ®Google Scholar
• Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med.352(4), 333–340 (2005).
   PubMed Web of Science ®Google Scholar
• Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg. Infect. Dis.13(9), 1348–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Kuiken T, Holmes EC, McCauley J et al. Host species barriers to influenza virus infections. Science312(5772), 394–397 (2006).
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin. (Epub ahead of print) (2009).
   PubMedGoogle Scholar
• Mayr A, Munz E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralbl Bakteriol [Orig.],195(1), 24–35 (1964).
   Google Scholar
• Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralbl. Bakteriol. [B]167(5–6), 375–390 (1978).
   PubMedGoogle Scholar
• Stickl H, Hochstein-Mintzel V. Ìntracuteneous smallpox vaccination with a weak pathogenic vaccinia virus (“MVA virus”). Munch. Med. Wochenschr.113, 1149–1153 (1971).
   PubMedGoogle Scholar
• Stickl H, Hochstein-Mintzel V, Mayr A et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA)]. Dtsch Med. Wochenschr.99(47), 2386–2392 (1974).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine25(51), 8562–8573 (2007).
   PubMed Web of Science ®Google Scholar
• Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine25(8), 1513–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Jones T. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Curr. Opin. Mol. Ther.10(4), 407–417 (2008).
   PubMedGoogle Scholar
• Stittelaar KJ, Kuiken T, de Swart RL et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine19(27), 3700–3709 (2001).
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA89(22), 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord.3(3), 263–271 (2003).
   PubMedGoogle Scholar
• Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol.15(6), 506–512 (2004).
   PubMed Web of Science ®Google Scholar
• Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther.8(2), 97–120 (2008).
   PubMed Web of Science ®Google Scholar
• Sandstrom E, Nilsson C, Hejdeman B et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis.198(10), 1482–1490 (2008).
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis.198(4), 544–552 (2008).
   PubMed Web of Science ®Google Scholar
• Jaoko W, Nakwagala FN, Anzala O et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine26(22), 2788–2795 (2008).
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res.13(15 Pt 1), 4487–4494 (2007).
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines7(7), 889–893 (2008).
   PubMed Web of Science ®Google Scholar
• Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol.74(16), 7651–7655 (2000).
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother.57(7), 977–986 (2008).
   PubMed Web of Science ®Google Scholar
• Sharpe S, Polyanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol.82(Pt 9), 2215–2223 (2001).
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol.77(1), 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Naito T, Kaneko Y, Kozbor D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol.88(Pt 1), 61–70 (2007).
   PubMed Web of Science ®Google Scholar
• Mooij P, Balla-Jhagjhoorsingh SS, Koopman G et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol.82(6), 2975–2988 (2008).
   PubMed Web of Science ®Google Scholar
• Tatsis N, Lin SW, Harris-McCoy K et al. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology367(1), 156–167 (2007).
   PubMed Web of Science ®Google Scholar
• Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western reserve strain and advantages as a vaccine. J. Virol.74(2), 923–933 (2000).
   PubMed Web of Science ®Google Scholar
• Albrecht M, Suezer Y, Staib C et al. Vaccination with a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. J. Gene Med.10(12), 1324–1333 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med.4(4), 397–402 (1998).
   PubMed Web of Science ®Google Scholar
• El-Gogo S, Staib C, Lasarte JJ, Sutter G, Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J. Gene Med.10(2), 177–186 (2008).
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol.81(21), 11925–11936 (2007).
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine25(11), 2120–2127 (2007).
   PubMed Web of Science ®Google Scholar
• Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine12(11), 1032–1040 (1994).
   PubMed Web of Science ®Google Scholar
• Hirsch VM, Fuerst TR, Sutter G et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol.70(6), 3741–3752 (1996).
   PubMed Web of Science ®Google Scholar
• Paran N, Suezer Y, Lustig S et al. Post-exposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. J. Infect. Dis.199(1), 39–48 (2009).
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Wyatt LS et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl Acad. Sci. USA105(31), 10889–10894 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine26(14), 1794–1804 (2008).
   PubMed Web of Science ®Google Scholar
• Waibler Z, Anzaghe M, Ludwig H et al. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol.81(22), 12102–12110 (2007).
   PubMed Web of Science ®Google Scholar
• Samuelsson C, Hausmann J, Lauterbach H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest.118(5), 1776–1784 (2008).
   PubMed Web of Science ®Google Scholar
• Guerra S, Najera JL, Gonzalez JM et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol.81(16), 8707–8721 (2007).
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Kastenmuller W, Kandemir JD et al. Modified vaccinia virus Ankara (MVA) triggers chemotaxisof monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol.83(6), 2540–2552 (2009).
   PubMed Web of Science ®Google Scholar
• Schnierle BS, Suezer Y, Sutter G. Recombinant poxvirus vaccines in biomedical research. In: Poxviruses. Mercer A, Schmidt A, Weber O (Eds). Birkhauser-Verl, Basel, Switzerland (2007).
   Google Scholar
• Staib C, Lowel M, Erfle V, Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques34(4), 694–696, 698, 700 (2003).
   PubMed Web of Science ®Google Scholar
• Domi A, Moss B. Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage λ-based recombination. Nat. Methods2(2), 95–97 (2005).
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Andersen RF, Spencer AJ et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE3(2), e1638 (2008).
   PubMed Web of Science ®Google Scholar
• Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J. Virol.80(15), 7676–7687 (2006).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology238(2), 198–211 (1997).
   PubMed Web of Science ®Google Scholar
• Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol.79(Pt 2), 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Okeke MI, Nilssen O, Traavik T. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J. Gen. Virol.87(Pt 1), 21–27 (2006).
   PubMed Web of Science ®Google Scholar
• Bender BS, Rowe CA, Taylor SF et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol.70(9), 6418–6424 (1996).
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Suezer Y, van Amerongen G et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis.195(11), 1598–1606 (2007).
   PubMed Web of Science ®Google Scholar
• Kreijtz JHCM, Süzer Y, de Mutsert G et al. Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis.199(3), 405–413 (2009).
   PubMed Web of Science ®Google Scholar
• Just I, Finke H. [A contribution to the stabilisation of the MVA-vaccine]. Zentralbl. Bakteriol. [Orig. A],245(3), 276–282 (1979).
   PubMedGoogle Scholar